Conmed (NASDAQ: CNMD) reported Q2 EPS of $0.46, $0.01 better than the analyst estimate of $0.45. Revenue for the quarter came in at $212.8 million versus the consensus estimate of $207.12 million.

GUIDANCE:

Conmed sees FY2018 EPS of $2.15-$2.20, versus the consensus of $2.17.

For earnings history and earnings-related data on Conmed (CNMD) click here.